| Product Code: ETC9950393 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Onco-hematology Molecular Testing Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Onco-hematology Molecular Testing Market - Industry Life Cycle |
3.4 United Kingdom (UK) Onco-hematology Molecular Testing Market - Porter's Five Forces |
3.5 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Type, 2021 & 2031F |
3.6 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Biomarker, 2021 & 2031F |
3.8 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 United Kingdom (UK) Onco-hematology Molecular Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer and hematological disorders in the UK |
4.2.2 Technological advancements in molecular testing leading to improved accuracy and efficiency |
4.2.3 Growing demand for personalized medicine and targeted therapies in onco-hematology |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for molecular testing in the UK |
4.3.2 High cost associated with onco-hematology molecular testing procedures |
4.3.3 Limited healthcare infrastructure and access to advanced testing facilities in certain regions of the UK |
5 United Kingdom (UK) Onco-hematology Molecular Testing Market Trends |
6 United Kingdom (UK) Onco-hematology Molecular Testing Market, By Types |
6.1 United Kingdom (UK) Onco-hematology Molecular Testing Market, By Blood Cancer Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Blood Cancer Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Chronic Myeloid Leukemia, 2021- 2031F |
6.1.4 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Myeloproliferative Neoplasms, 2021- 2031F |
6.1.5 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Acute Myeloid Leukemia, 2021- 2031F |
6.1.6 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Acute Lymphoblastic Leukemia, 2021- 2031F |
6.2 United Kingdom (UK) Onco-hematology Molecular Testing Market, By Technology |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By qPCR, 2021- 2031F |
6.2.3 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By dPCR, 2021- 2031F |
6.2.4 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Next-Generation Sequencing, 2021- 2031F |
6.2.5 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United Kingdom (UK) Onco-hematology Molecular Testing Market, By Blood Cancer Biomarker |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By BCR-ABL1 Mbcr, 2021- 2031F |
6.3.3 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By JAK2, 2021- 2031F |
6.3.4 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By CALR, 2021- 2031F |
6.3.5 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By MPL, 2021- 2031F |
6.3.6 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By PML-RARA, 2021- 2031F |
6.3.7 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By NPM1, 2021- 2031F |
6.3.8 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By CBFB-MYH11, 2021- 2031F |
6.3.9 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By CBFB-MYH11, 2021- 2031F |
6.4 United Kingdom (UK) Onco-hematology Molecular Testing Market, By End-user |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By National Reference Lab / Specialty Lab, 2021- 2031F |
6.4.3 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By University Hospital / Oncology Center, 2021- 2031F |
6.4.4 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenues & Volume, By Community Hospital / IDN (Regional/National), 2021- 2031F |
7 United Kingdom (UK) Onco-hematology Molecular Testing Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Onco-hematology Molecular Testing Market Export to Major Countries |
7.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Imports from Major Countries |
8 United Kingdom (UK) Onco-hematology Molecular Testing Market Key Performance Indicators |
8.1 Adoption rate of molecular testing technologies in onco-hematology |
8.2 Rate of integration of genetic profiling in treatment decision-making processes |
8.3 Number of partnerships between research institutions, healthcare providers, and technology companies to drive innovation in molecular testing |
9 United Kingdom (UK) Onco-hematology Molecular Testing Market - Opportunity Assessment |
9.1 United Kingdom (UK) Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Type, 2021 & 2031F |
9.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.3 United Kingdom (UK) Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Biomarker, 2021 & 2031F |
9.4 United Kingdom (UK) Onco-hematology Molecular Testing Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 United Kingdom (UK) Onco-hematology Molecular Testing Market - Competitive Landscape |
10.1 United Kingdom (UK) Onco-hematology Molecular Testing Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Onco-hematology Molecular Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here